Natus Medical Beats Analyst Estimates on EPS
Natus Medical (NAS: BABY) reported earnings on Feb. 28. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Natus Medical missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share grew significantly. GAAP earnings per share increased.
Margins increased across the board.
Natus Medical chalked up revenue of $90.5 million. The three analysts polled by S&P Capital IQ hoped for sales of $93.6 million on the same basis. GAAP reported sales were 41% higher than the prior-year quarter's $64.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.29. The three earnings estimates compiled by S&P Capital IQ anticipated $0.26 per share. Non-GAAP EPS of $0.29 for Q4 were 107% higher than the prior-year quarter's $0.14 per share. GAAP EPS were $0.16 for Q4 versus -$0.60 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 56.5%, 110 basis points better than the prior-year quarter. Operating margin was 9.3%, 10 basis points better than the prior-year quarter. Net margin was 5.3%, much better than the prior-year quarter.
Next quarter's average estimate for revenue is $83.7 million. On the bottom line, the average EPS estimate is $0.09.
Next year's average estimate for revenue is $362.1 million. The average EPS estimate is $0.83.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,236 members out of 1,266 rating the stock outperform, and 30 members rating it underperform. Among 363 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 353 give Natus Medical a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Natus Medical is hold, with an average price target of $16.00.
Is Natus Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Natus Medical to My Watchlist.
The article Natus Medical Beats Analyst Estimates on EPS originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool recommends Natus Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.